Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 – an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently for people living with obesity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
- Eli Lilly, others to buy after RFK-inspired drop, Barron’s says
- Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer
- Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs
- Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs